Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018” | CMAC

Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):134-146

​ Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Edelstein M.V., Perepanova T.S., Kozlov R.S., “DARMIS-2018” Study Group
10.36488/cmac.2019.2.134-146
community-acquired urinary tract infections uropathogens Escherichia coli antimicrobial resistance
Section
Antimicrobial Resistance
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):134-146

Objective.

To study in vitro activity of antimicrobials against clinical isolates from patients with communityacquired urinary tract infections (UTIs) in different regions of Russia in 2017–2018.

Materials and Methods.

A total of 1052 Enterobacterales isolates collected in the Russian Federation as part of a multicenter, prospective, epidemiological study of the antimicrobial resistance of uropathogens causing community-acquired UTI in different subsets of patients (“DARMIS-2018”) were included in the analysis. Uropathogens were isolated from children and adults of both sexes in all age groups with acute (and recurrences of chronic) community-acquired UTIs, including pregnant women with asymptomatic bacteriuria in 32 centers of 24 cities of Russia in 2017–2018.

Results.

Enterobacterales comprised a total of 90.6% of all isolated bacterial pathogens (90.6% in the adult subset; 89.3% in the pregnant women subset and 93.8% in the children and adolescents subset). The most prevalent species were Escherichia coli (71.3% in the adult subset; 73.6% in the pregnant women subset; 79.7% in the children and adolescents subset) and Klebsiella pneumoniae (11.7% in the adult subset; 10.4% in the pregnant women subset; 7.8% in the children and adolescents subset). The highest activity against E. coli among the oral antimicrobials was demonstrated for fosfomycin (97.7% in the adult subset; 95.9% in the pregnant women subset; 99.0% in the children and adolescents subset) and nitrofurantoin (98.1% in adult subset; 100% in the pregnant women subset; 97.1% in the children and adolescents subset). Among the parenteral antimicrobials, meropenem and amikacin showed the highest activity (99.4% and 97.9% in the adult subset; 99.5% and 99.1% in the pregnant women subset; 100% and 97.1% in the children and adolescents subset, respectively). Ampicillin, amoxicillin/clavulanic acid and trimethoprim/sulfamethoxazole demonstrated the lowest in vitro activity against E. coli (less than 80% per each patient subset). The susceptibility of E. coli isolates to ciprofloxacin was 60.6% in the adult subset; 80.0% in the pregnant women subset and 80.4% in the children and adolescents subset. The rates of extended spectrum beta-lactamase production based on the results of phenotypic tests were 27.0% in the adult subset; 8.6% in the pregnant women subset and 23.5% in the children and adolescents subset.

Conclusions.

Results of this study indicated the increase in resistance of community-acquired isolates of Enterobacterales (particularly E. coli) to the most of antimicrobials in Russia.

Ivan S. Palagin

Smolensk State Medical University, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Marina V. Sukhorukova

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Andrey V. Dekhnich

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Mikhail V. Edelstein

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Perepanova T.S.

Institute of Urology and Interventional Radiology named after N.A. Lopatkin, Moscow, Russia

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

“DARMIS-2018” Study Group

Mutin M.YU. (OGAUZ «BGB№1», Bratsk), Strebkova V.V. (BUZ VO «VGKBSMTP №10», Voronezh), Amineva P.G. (OOO «Kvoliti Med», Ekaterinburg), Vetohina A.V. (GBUZ «IOKB», Irkutsk), Suhoreva M.V. (OGAUZ «GIMDKB», Irkutsk), Ivanova I.A. (GBU RME «RCPB SPID i IZ», Joshkar-Ola), Valiullina I.R. (GAUZ «RKB MZ RT», Kazan'), CHastoedova A.N. (KOGBUZ «KOKB», Kirov), SHirokova T.M. (KOGBUZ «KOKPC», Kirov), Varibrus E.V. (GBUZ «KKB№2» MZ KK, Krasnodar), Vasil'eva I.R. (BU HMAO-YUgry «NOKDB», Nizhnevartovsk), Domanskaya O.V. (GBUZ KO «NGDKB№4», Novokuzneck), Bekker G.G. (NUZ «DKB na st. Novosibirsk-Gl.» OAO «RZHD», Novosibirsk), Kul'chavenya E.V. (FGBU «NNIIT» Minzdrava Rossii, FGBOU VO «NGMU» Minzdrava Rossii, Novosibirsk), Plugin P.S. (GBUZ NO «GKBSMP№2», Novosibirsk), Popova L.D. (BUZ OO «OKB», Omsk), Elohina E.V. (BUZ OO «OKB», FGBOU VO «OmGMU» Minzdrava Rossii, Omsk), Kogan M.I., Naboka YU.L. (FGBOU VO «RostGMU» Minzdrava Rossii, Rostov-na-Donu), ZHestkov A.V., Lyamin A.V. (FGBOU VO «SamGMU» Minzdrava Rossii,Samara), Husnutdinova T.A., SHipicyna E.V. (FGBU «NII AGiR im. D.O. Otta», FGBOU VO «SPbGPMU» Minzdrava Rossii, Sankt-Peterburg),Bulkin A.N. (SPbGBUZ «GB Svyatogo Velikomuchenika Georgiya», Sankt-Peterburg), Moskvitina E.N. (FGBU SibFNKC FMBA Rossii, Seversk),Nikiforovskaya N.N. (NUZ OB na st. Smolensk OAO «RZHD», Smolensk), Malev I.V. (OBGUZ «Poliklinika №3», Smolensk), Varganova A.N.(BU «SOKB», Surgut), Mart'yanova N.M. (GBUZ SO «TGKB№5», Tol'yatti), Bykonya S.A., Volkovskaya I.V. (OGAUZ «TOKB», Tomsk), MalyavinA.I., Sidorova R.K. (GUZ «GP№4», Ul'yanovsk), Hajdarshina N.E. (FGBOU VO «CHelGU», CHelyabinsk), SHamaeva S.H., Portnyagina U.S. (GBU RS(YA) «RB№2-CEMP», YAkutsk), Ershova M.G. (GBUZ YAO «IKB», YAroslavl')

  • 1. Schito G.C., Naber K.G., Botto H., Palou J., Mazzei T., Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34:407-413.
  • 2. Kahlmeter G., ECO.SENS. An international survey on the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003;51:69-76.
  • 3. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., et al. DARMIS Study Group. Current state of antibiotic resistance of pathogens causing community-aquired urinary tract infections in Russia: “DARMIS” Study (2010-2011). Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2012;14(4):280-302. Russian.
  • 4. Ny S., Edquist P., Dumpis U., et al. Antibiotic resistance of Escherichia coli from outpatient urinary tract infection in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25-34.
  • 5. Hooton T.M. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028-1037.
  • 6. Laupland K.B., Ross T., Pitout J.D., Church D.L., Gregson D.B. Community-onset urinary tract infections: a population-based assessment. Infection. 2007;35(3):150-153.
  • 7. Ny S., Kozlov R., Dumpis U., et al. “NoDARS ESBL-carrier Working Group. Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia. Eur J Clin Microbiol Infect Dis. 2018;37(12):2347-2354.
  • 8. Lob S.H., Nicolle L.E., Hoban D.J., et al. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014. Diagn Microbiol Infect Dis. 2016;85(4):459-465.
  • 9. ISO 20776-1:2006 "Clinical laboratory testing and in vitro diagnostic test systems – Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices – Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases.
  • 10. GOST R ISO 20776-1-2010 Clinical laboratory testing and in vitro diagnostic test systems. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 1. Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. Russian.
  • 11. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. Available at: http://www.eucast.org/clinical_breakpoints/
  • 12. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Ver 2.0. 2017. Available at: www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf. Accessed June 24, 2019.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared